- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 16:46 | FDA approves first gene therapy for Sanfilippo syndrome type A | ||
| 12:46 | Novo targets oral macrocycles with $1.4bn Orbis partnership | ||
| 11:46 | Ona Therapeutics to develop ADC with WuXi's payload-linker platform | ||
| 10:46 | Roche agrees $1bn deal with Dualitas for bispecific antibody research | ||
| Do | Novo taps Anthropic's Claude to 'supercharge' R&D efforts | ||
| Do | Cellares and GenomeFrontier to assess automated GF-CART01 production | ||
| Do | Viatris' Wakix receives Japanese approval to treat OSAS and narcolepsy | ||
| Mi | Sling ropes in $123m for oral thyroid eye disease drug | ||
| Mi | Gilead and PAHO agree to expedite lenacapavir access for HIV prevention | ||
| Mi | Eli Lilly and QurCan sign genetic medicine deal | ||
| Di | Electra Therapeutics targets $342m IPO to fund hyperinflammatory syndrome drug's pivotal trials | ||
| Di | Agentic AI trust gap slowing healthcare provider adoption, survey reveals | ||
| Di | GSK bolsters oncology pipeline with $750m Chimagen TCE deal | ||
| Di | Definium tees up regulatory submission for psychedelic on Phase III hat trick | ||
| Di | Cheplapharm to take over 20 medicines and three sites from Sanofi | ||
| Di | FDA reduces monitoring time for Amgen's Imdelltra infusions | ||
| Mo | No more Nordisk: Novo's latest trim is in its name | ||
| Mo | Scholar Rock's muscle-targeting SMA therapy Isemblyd lands FDA approval | ||
| 11.09. | HIV charities lament NICE snub for Gilead's twice-yearly lenacapavir | ||
| 11.09. | Exegenesis Bio and Modalis sign research deal for Duchenne therapy | ||
| 11.09. | ABEC to expand global manufacturing network with new Wilson facility | ||
| 10.09. | Encoded secures $275m for Dravet syndrome gene therapy | ||
| 10.09. | Bayer's Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion | ||
| 10.09. | HHS appoints permanent FDA CBER, CDER heads | ||
| 10.09. | Solstice Oncology secures $225m to drive porustobart's development for cancer |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.